NCT01457547已完成4 期
Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 494
- 试验地点
- 10
- 主要终点
- Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations
研究概览
简要总结
The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 8 Weeks 至 15 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A healthy male or female subject between 8 and 15 weeks of age at the time of the first vaccination.
- •Written informed consent obtained from the parent or guardian of the subject prior to the study entry.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Born after a normal gestation period between 36 and 42 weeks.
排除标准
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period.
- •Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib vaccination or disease.
- •Planned administration of a vaccine not foreseen by the study protocol since birth and during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose of the three-dose primary vaccination course, with the exception of licensed Neisseria meningitides conjugate vaccines or Bacillus Calmette-Guérin (BCG) vaccine that can be given in between study visits or after the third visit, provided they are given preferably with a 4 weeks interval but not less than 3 weeks apart from the study vaccine doses.
- •Chronic administration or planned administration of immuno-suppressants or other immune-modifying drugs since birth.
- •Planned administration of immunoglobulins and/or any blood products since birth or planned administration during the period up to 30 days after the third dose of the primary vaccination course.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of seizures, progressive neurological disease or intra-cerebral haemorrhage.
- •Major congenital defects or serious chronic illness.
- •Acute febrile illness at the time of planned vaccination
- •History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.
结局指标
主要结局
Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations
时间窗: Prior to the third primary vaccination dose ( Months 8-9)
次要结局
- Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations(One month after the second and third primary vaccination dose (Month 3 and Months 9-10))
- Immunogenicity with respect to the components of the study vaccine in terms of number of seroprotected subjects defined by antibody concentration(Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10))
- Immunogenicity with respect to the components of the study vaccine in terms of number of seropositive subjects(Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10))
- Occurrence of solicited symptoms(Within 4 days (Day 0 -Day 3) after each vaccine dose)
- Occurrence of a grade "3" solicited symptoms(Within 4 days (Day 0 -Day 3) after each vaccine dose)
- Occurrence of unsolicited adverse events(Within 31 days after any vaccination)
- Occurrence of Serious Adverse Events(Throughout the entire study up to (Month 0 to Month 9-10) and including 30 days after last vaccination (Month 9-10))
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in AdultsHepatitis BNCT00696891GlaxoSmithKline380
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 yHepatitis BNCT00698555GlaxoSmithKline163
已完成
3 期
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccinePoliomyelitisAcellular PertussisHaemophilus Influenzae Type bDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b VaccinesHepatitis BTetanusDiphtheriaNCT01353703GlaxoSmithKline224
Unknown
3 期
Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy AdultHealthyNCT02553837Green Cross Corporation317
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 yHepatitis BNCT00698906GlaxoSmithKline160